Kyverna Therapeutics (NASDAQ: KYTX) insider transactions
In the twelve months to 10 November 2026, executives and directors of Kyverna Therapeutics reported 1 open-market sale of 23,998 shares ($292,776) and 2 open-market purchases of 266,666 shares ($2.0m), by 3 people, according to the Form 4 filings they submitted to the SEC.
Latest transactions
| Date | Insider | Role | Transaction | Shares | Price | Held after | Filing |
|---|---|---|---|---|---|---|---|
| 27 May 2026 | Aktar Mert | Director | Grant or award | +5,093 | — | 21,727 | Form 4 |
| 27 May 2026 | Shaw Christi | Executive Chairperson | Shares withheld for tax | −4,194 | $8.59 | 66,741 | Form 4 |
| 27 May 2026 | Seidenberg Beth C | Director | Grant or award | +5,093 | — | 21,727 | Form 4 |
| 27 May 2026 | Cohen Fred E | Director | Grant or award | +5,093 | — | 21,727 | Form 4 |
| 27 May 2026 | Clark Ian T | Director | Grant or award | +5,093 | — | 21,727 | Form 4 |
| 13 March 2026 | Biddle Warner Weston | Chief Executive Officer | Grant or award | +58,000 | — | 58,000 | Form 4 |
| 13 March 2026 | Grasso Marc | Chief Financial Officer | Grant or award | +10,000 | — | 10,000 | Form 4 |
| 13 March 2026 | Gehchan Naji | See Remarks | Grant or award | +18,000 | — | 18,000 | Form 4 |
| 24 February 2026 | Miller Andrew Craig | Director | Grant or award | +11,006 | — | 11,006 | Form 4 |
| 24 February 2026 | Emany Sravan Kumar | Director | Grant or award | +11,006 | — | 11,006 | Form 4 |
| 12 January 2026 | Shaw Christi | Executive Chairperson | Grant or award | +30,000 | — | 46,634 | Form 4 |
| 12 January 2026 | Shaw Christi | Executive Chairperson | Grant or award | +24,301 | — | 70,935 | Form 4 |
| 18 December 2025 | Westlake BioPartners Opportunity Fund I, L.P. | — | Open-market purchase | +133,333 | $7.50 | 869,317 | Form 4 |
| 18 December 2025 | Seidenberg Beth C | Director | Open-market purchase | +133,333 | $7.50 | 869,317 | Form 4 |
| 15 December 2025 | Walker Karen Marie | Chief Technology Officer | Option exercise | +23,998 | $4.83 | 46,634 | Form 4 |
| 15 December 2025 | Walker Karen Marie | Chief Technology Officer | Open-market sale | −23,998 | $12.20 | 22,636 | Form 4 |
| 29 May 2025 | Cohen Fred E | Director | Grant or award | +16,634 | — | 16,634 | Form 4 |
| 29 May 2025 | Clark Ian T | Director | Grant or award | +16,634 | — | 16,634 | Form 4 |
| 29 May 2025 | Aktar Mert | Director | Grant or award | +16,634 | — | 16,634 | Form 4 |
| 29 May 2025 | Spiegelman Daniel K | Director | Grant or award | +16,634 | — | 16,634 | Form 4 |
Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.
How to read the table
Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.
Where each row comes from
From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Kyverna Therapeutics page; the method, in data sources.
Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.